Employees: 11 (2023.0)Legal category: 5485Size: PMECreation date: 2003-02-01 (23 years)Status: ActiveBusiness sector: Commerce de détail de produits pharmaceutiques en magasin spécialiséLocation: ETREPAGNY (27150), Eure
PHARMACIE THIEBAULT-HARDY : revenue, balance sheet and financial ratios
PHARMACIE THIEBAULT-HARDY is a French company
founded 23 years ago,
specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé.
Based in ETREPAGNY (27150),
this company of category PME
shows in 2023 a revenue of 4.7 M€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Financial history - PHARMACIE THIEBAULT-HARDY (SIREN 445238298)
Indicator
2025
2024
2023
2022
2020
2019
2018
Revenue
N/C
N/C
4 705 514 €
N/C
N/C
N/C
3 838 671 €
Net income
693 750 €
489 753 €
410 486 €
466 560 €
306 286 €
427 508 €
360 314 €
EBITDA
N/C
N/C
562 013 €
N/C
N/C
N/C
562 506 €
Net margin
N/C
N/C
8.7%
N/C
N/C
N/C
9.4%
Revenue and income statement
In 2025, PHARMACIE THIEBAULT-HARDY generates positive net income of 694 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2018-2025: 360 k€ -> 694 k€.
Net income (2025)
?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax
693 750 €
Loading income statement...
Income statement
Item
Amount
% Revenue
Change
The detailed income statement is not available for this company (simplified accounts or confidential data).
Chart evolution
Show :
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Assets
Loading data...
Item
Gross
Deprec.
Net
%
Change
Assets balance sheet data not available for this company
Liabilities
Loading data...
Item
Year
%
Change
Liabilities balance sheet data not available for this company
Solvency and debt ratios
The debt ratio (= Financial debt / Equity x 100) stands at 98%. Debt level is high: negotiating margin with banks is reduced. Financial autonomy (= Equity / Total assets x 100) reaches 46%. This high autonomy means the company finances most of its assets through equity, a sign of strength.
Debt ratio (2025)
?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low 50-100% : Moderate > 100% : High
98.282%
Financial autonomy (2025)
?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy 20-30% : Average < 20% : Low
45.694%
Asset age ratio (2025)
?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2018
2019
2020
2022
2023
2024
2025
Debt ratio
19.177
15.901
8.278
2.262
5.537
63.166
98.282
Financial autonomy
75.104
79.202
84.34
83.946
66.832
44.143
45.694
Repayment capacity
1.168
None
None
None
0.297
None
None
Cash flow / Revenue
10.415%
None%
None%
None%
9.106%
None%
None%
Sector positioning
Debt ratio
98.282025
2023
2024
2025
Q1: 13.71
Med: 49.76
Q3: 129.07
Average+40 pts over 3 years
In 2025, the debt ratio of PHARMACIE THIEBAULT-HARDY (98.28) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
Financial autonomy
45.69%2025
2023
2024
2025
Q1: 33.42%
Med: 53.71%
Q3: 72.08%
Average-33 pts over 3 years
In 2025, the financial autonomy of PHARMACIE THIEBAULT-HARDY (45.7%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.
Repayment capacity
0.3 years2023
2023
Q1: 0.95 years
Med: 3.58 years
Q3: 7.48 years
Excellent
In 2023, the repayment capacity of PHARMACIE THIEBAULT-HARDY (0.30) ranks in the bottom 25% of the sector, which is positive. This ratio indicates the number of years needed to repay debt with cash flow. A short capacity reflects controlled debt and good cash generation.
Liquidity ratios
The liquidity ratio (= Current assets / Current liabilities) stands at 336.91. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
Liquidity ratio (2025)
?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good 1-1.5 : Fair < 1 : Liquidity risk
Visualisation créée via abddaf.fr Sources : INPI & BCE - Retraitements : Ministère de l'économie
Indicator
2018
2019
2020
2022
2023
2024
2025
Liquidity ratio
416.439
563.899
568.924
288.64
156.339
99.926
336.91
Interest coverage
1.711
None
None
None
0.562
None
None
Sector positioning
Liquidity ratio
336.912025
2023
2024
2025
Q1: 131.03
Med: 182.29
Q3: 258.7
Excellent+40 pts over 3 years
In 2025, the liquidity ratio of PHARMACIE THIEBAULT-HARDY (336.91) ranks in the top 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio above 1 ensures comfortable coverage of short-term maturities.
Interest coverage
0.56x2023
2023
Q1: 0.38x
Med: 2.71x
Q3: 6.47x
Average
In 2023, the interest coverage of PHARMACIE THIEBAULT-HARDY (0.6x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.
Working capital requirement (WCR) and payment terms
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.
Operating WCR (2025)
?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released Positive = financing needed
0 €
Customer credit (2025)
?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good 45-60j : Average > 60j : Long
0 j
Supplier credit (2025)
?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow
0 j
Inventory turnover (2025)
?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover
0 j
WCR and payment terms evolution PHARMACIE THIEBAULT-HARDY
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2018
2019
2020
2022
2023
2024
2025
Operating WCR
506 474 €
0 €
0 €
0 €
-52 890 €
0 €
0 €
Inventory turnover (days)
22
0
0
0
24
0
0
Customer payment term (days)
5
0
92
0
6
0
0
Supplier payment term (days)
39
0
509
0
33
0
0
Positioning of PHARMACIE THIEBAULT-HARDY in its sector
Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé
Valuation estimate
Based on 277 transactions of similar company sales
in 2025,
the value of PHARMACIE THIEBAULT-HARDY is estimated at
11 020 301 €
(range 7 478 428€ - 17 292 370€).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Estimated enterprise value2025
277 transactions
7478k€11020k€17292k€
11 020 301 €Range: 7 478 428€ - 17 292 370€
NAF 5 année 2025
Valuation method used
Net Income Multiple
693 750 €
×
15.9x
=11 020 301 €
Range: 7 478 428€ - 17 292 370€
Only this financial indicator is available for this company.
Valuation evolution
Visualisation creee via abddaf.fr Sources : BODACC & INPI
How is this estimate calculated?
This estimate is based on the analysis of 277 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
Net Income Multiple: Relevant for mature companies with stable results.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)
Compare PHARMACIE THIEBAULT-HARDY with other companies in the same sector:
Frequently asked questions about PHARMACIE THIEBAULT-HARDY
What is the revenue of PHARMACIE THIEBAULT-HARDY ?
The revenue of PHARMACIE THIEBAULT-HARDY in 2023 is 4.7 M€.
Is PHARMACIE THIEBAULT-HARDY profitable?
Yes, PHARMACIE THIEBAULT-HARDY generated a net profit of 694 k€ in 2025.
Where is the headquarters of PHARMACIE THIEBAULT-HARDY ?
The headquarters of PHARMACIE THIEBAULT-HARDY is located in ETREPAGNY (27150), in the department Eure.
Where to find the tax return of PHARMACIE THIEBAULT-HARDY ?
The tax return of PHARMACIE THIEBAULT-HARDY is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does PHARMACIE THIEBAULT-HARDY operate?
PHARMACIE THIEBAULT-HARDY operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.
Item evolution
Rotate your phone to landscape mode to view the chart